This week's View summarizes the ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) and GLOBAL LEADERS trials and an article about the variability of left ventricular (LV) ejection fraction measured by different imaging modalities in patients with LV dysfunction.

Subscribe on iTunes | Subscribe on Google Play

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and ACS, Acute Heart Failure, Interventions and ACS, Interventions and Coronary Artery Disease, Interventions and Imaging, Angiography, Computed Tomography, Echocardiography/Ultrasound, Magnetic Resonance Imaging, Nuclear Imaging

Keywords: EaglesEyeView, ESC Congress, ESC18, Acute Coronary Syndrome, Aspirin, Adenosine, Anticoagulants, Coronary Artery Disease, Coronary Disease, Diagnostic Imaging, Drug-Eluting Stents, Echocardiography, Heart Failure, Magnetic Resonance Imaging, Myocardial Infarction, Myocardial Ischemia, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Primary Prevention, Risk, Secondary Prevention, Stroke Volume, Tomography, Emission-Computed, Single-Photon, Ventricular Dysfunction, Left, Angiography

< Back to Listings